Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation
The clinical development of the meningococcal vaccine, 4CMenB, included 2 doses in vaccine-naïve adolescents, which was considered unlikely to be cost-effective for implementation. Theoretically, priming with 4CMenB in early childhood might drive strong immune responses after only a single booster d...
Päätekijät: | , , , , , , , , , , , , , , , |
---|---|
Aineistotyyppi: | Journal article |
Kieli: | English |
Julkaistu: |
Elsevier
2022
|